enGene Holdings Inc. Warrants

enGene Holdings Inc. Warrants reported a net loss of $29.8 million for Q1 2026, driven by total operating expenses of $31.2 million, primarily from research and development ($22.3 million) and general and administrative costs ($8.9 million). The loss from operations was partially offset by total other income, net of $1.4 million, which included interest income of $2.7 million. The company ended the quarter with total assets of $337.1 million, including cash and cash equivalents of $36.6 million and marketable securities totaling $275.9 million. Total liabilities stood at $55.6 million, resulting in shareholders' equity of $281.5 million. Cash flow from operations was negative $28.9 million, while financing activities provided $141.7 million primarily from a public offering ($126.2 million) and a Second Amended Term Loan ($25.0 million). The company's cash position decreased by $13.5 million during the quarter to $50.2 million.

Key Takeaways